Home - Open Targets

Open Targets is an innovative, large-scale, multi-year, public-private partnership that uses human genetics and genomics data for systematic drug target identification and prioritisation.

Visit the Open Targets Platform which integrates public domain data to enable target identification and prioritisation, or Open Targets Genetics which identifies targets based on GWAS and functional genomics. We complement data integration with large scale systematic experimental approaches to support target identification, prioritisation and validation. Check out our latest papers describing our experimental target identification approaches in oncology, neurodegeneration, and immunity and inflammation.

Find targets for a given disease
Visit the Open Targets Platform Discover genetic evidence for targets
Visit Open Targets Genetics Explore our research projects
Read our publications

News

Graphic showing predicted trial stop reasons in rows with counts of trials per start year, clinical phase or therapeutic area shown by the color in each cell. The outcome groupings of the stopped reasons are shown using the color next to the stopped reason label.

Why clinical trials stop: the role of genetics

29 July 2024

Using machine learning to analyse the genetic factors behind early clinical trial termination, researchers find a link between genetic evidence and trial outcome.

Failure is the most likely outcome of a clinical trial. Learning from these failures by understanding which factors maximise the chances of a successful trial would help improve the drug discovery process. However, accessing information about failed clinical trials is difficult since the dr...

Our Partners

At the heart of Open Targets is a consortium of complementary partner institutions that bring their respective expertise to collaborative projects that improve how we systematically identify and prioritise drug targets.